Validation of dominant and secondary sequence utilization in PI-RADS v2 for classifying prostatic lesions
Nachiketh Soodana-Prakash1, R. Patricia Castillo2, Isildinha M. Reis3,4, Radka Stoyanova3,5, Deukwoo Kwon3, Maria C. Velasquez2, Bruno Nahar1, Pratik Kannabur1, Taylor A. Johnson1, Sanjaya K. Swain1,3, Natalie Ben-Yakar1, Vivek Venkatramani1, Chad Ritch1,3, Ramgopal Satyanarayana1,3, Mark L. Gonzalgo1,3, Dipen J. Parekh1,3, Leonardo Bittencourt6, Sanoj Punnen1,3
Canadian Journal of Urology, Vol.26, No.3, pp. 9763-9768, 2019
Abstract Introduction: To assess the secondary sequence rule in The Prostate Imaging Reporting Data System (PI-RADS) version 2 by comparing the detection of Grade group 1+ (GG1+) and 2+ (GG2+) cancers in PI-RADS 3, an upgraded PI-RADS 4, and true (non-upgraded) PI-RADS 4 targets.
Materials and methods: We analyzed a total of 589 lesions scored as PI-RADS 3 or 4 obtained from 434 men who underwent mpMRI-US fusion biopsy from September 2015 to November 2017 for evaluation of GG1+ and GG2+ prostate cancer. PI-RADS 4 lesions were differentiated into those that were “upgraded” to PI-RADS 4 based on… More >